Kazatomprom Reports 17 Production Increase in Third Quarter Signals Strong Uranium Output Workday Shares Surge on Raised Margin Forecast Amid AIDriven Growth Nvidia Dominance in Focus Market Expert Phil Rosen Offers Perspective After Earnings Mercury Fintech Firm Achieves 52 Billion Valuation After Latest Funding Round US Seeks to Expand AI Integration in Asia Following TrumpXi Talks Intelligent NBFCs How AI and Data Are Powering Indias Next Credit Cycle Five9 Q1 2026 Earnings EPS Surpasses Estimates by 913 as Stock Gains 421 Bain Capital Specialty Finance Inc BCSF Q1 2026 Earnings Net Investment Income Misses Estimates Stock Edges Higher CPRI Q1 2026 Earnings EPS Surpasses Estimates Stock Edges Higher FTAIM Q1 2026 Earnings Preferred Dividend Coverage Tightens as EPS Misses Estimates by 15 WHLRL Q2 2024 Earnings Strong EPS Performance Amidst Unique Capital Structure CC Q1 2026 Earnings Significant EPS Beat Driven by Operational Improvements FLC Inches Higher as ClosedEnd Fund Gains on Income Demand CTO Realty Growth Inc CTO Edges Higher as Stock Holds Above Key Support Level Dolby Laboratories DLB Climbs 12 as Shares Hold Above Key Support JM Smucker SJM Slips 1 as Consumer Staples Weaken Amid Defensive Rotation Ibotta IBTA Gains Momentum Testing Key Resistance Level NBCC Reports 388 YoY Profit Growth in Q4 Declares Dividend of 046 per Share Shift4 Payments Q1 2026 Earnings EPS Falls Short of Estimates Stock Declines Federal Signal FSS Holds Near Support After Modest Decline Mitek Systems MITK Q1 2026 Earnings EPS Beats Estimates as Stock Gains 436 Zillow Group ZG Q1 2026 Earnings EPS Surges Past Estimates But Stock Dips on Broader Market Headwinds KRYS Q1 2026 Earnings EPS Surges Past Estimates Driving Modest Stock Uptick V Q1 2026 Earnings Earnings Beat Estimates Stock Slightly Soft ANI Pharmaceuticals Q1 2026 Earnings Strong EPS Beat Highlights Operational Strength Core Scientific CORZ Q1 2026 Earnings Significant EPS Miss Despite Positive Stock Reaction FBRX Q1 2026 Earnings WiderthanExpected Loss Reflects PreRevenue Biotech Reality